Literature DB >> 15030527

Cathepsin D is up-regulated in inflammatory bowel disease macrophages.

M Hausmann1, F Obermeier, K Schreiter, T Spottl, W Falk, J Schölmerich, H Herfarth, P Saftig, G Rogler.   

Abstract

Down-regulation of receptors involved in the recognition or transmission of inflammatory signals and a reduced responsiveness support the concept that macrophages are 'desensitized' during their differentiation in the intestinal mucosa. During inflammatory bowel disease (IBD) intestinal macrophages (IMACs) change to a reactive or 'aggressive' type. After having established a method of isolation and purification of IMACs, message for cathepsin D was one of the mRNAs we found to be up-regulated in a subtractive hybridization of Crohn's disease (CD) macrophages versus IMACs from control mucosa. The expression of cathepsin D in intestinal mucosa was analysed by immunohistochemistry in biopsies from IBD and control patients and in a mouse model of dextran sulphate sodium (DSS)-induced acute and chronic colitis. IMACs were isolated and purified from normal and inflamed mucosa by immunomagnetic beads armed with a CD33 antibody. RT-PCR was performed for cathepsin D mRNA. Results were confirmed by Northern blot and flow cytometrical analysis. Immunohistochemistry revealed a significant increase in the cathepsin D protein expression in inflamed intestinal mucosa from IBD patients compared to non-inflamed mucosa. No cathepsin D polymerase chain reaction (PCR) product could be obtained with mRNA from CD33-positive IMACs from normal mucosa. Reverse transcription (RT)-PCR showed an induction of mRNA for cathepsin D in purified IMACs from IBD patients. Northern blot and flow cytometry analysis confirmed these results. Cathepsin D protein was also found in intestinal mucosa in acute and chronic DSS-colitis but was absent in normal mucosa. This study shows that expression of cathepsin D is induced in inflammation-associated IMACs. The presence of cathepsin D might contribute to the mucosal damage in IBD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15030527      PMCID: PMC1808992          DOI: 10.1111/j.1365-2249.2004.02420.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

Review 1.  Proteases involved in MHC class II antigen presentation.

Authors:  J A Villadangos; R A Bryant; J Deussing; C Driessen; A M Lennon-Duménil; R J Riese; W Roth; P Saftig; G P Shi; H A Chapman; C Peters; H L Ploegh
Journal:  Immunol Rev       Date:  1999-12       Impact factor: 12.988

2.  Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages.

Authors:  M Hausmann; T Spöttl; T Andus; G Rothe; W Falk; J Schölmerich; H Herfarth; G Rogler
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

3.  Immunohistochemical localization of cathepsin D in colorectal tumors.

Authors:  J Arao; H Fukui; Y Ono; Y Ueda; T Chiba; T Fujimori
Journal:  Dis Colon Rectum       Date:  2000-03       Impact factor: 4.585

4.  Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.

Authors:  N Harbeck; U Alt; U Berger; A Krüger; C Thomssen; F Jänicke; H Höfler; R E Kates; M Schmitt
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

5.  Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

Authors:  L Steidler; W Hans; L Schotte; S Neirynck; F Obermeier; W Falk; W Fiers; E Remaut
Journal:  Science       Date:  2000-08-25       Impact factor: 47.728

Review 6.  New functional aspects of cathepsin D and cathepsin E.

Authors:  T Tsukuba; K Okamoto; Y Yasuda; W Morikawa; H Nakanishi; K Yamamoto
Journal:  Mol Cells       Date:  2000-12-31       Impact factor: 5.034

7.  Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice.

Authors:  P Saftig; E Hunziker; V Everts; S Jones; A Boyde; O Wehmeyer; A Suter; K von Figura
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

8.  Expression of cathepsin B and cystatin C in human breast cancer.

Authors:  M Yano; K Hirai; Z Naito; M Yokoyama; T Ishiwata; Y Shiraki; M Inokuchi; G Asano
Journal:  Surg Today       Date:  2001       Impact factor: 2.549

9.  Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis.

Authors:  M Kaneko; T Tomita; T Nakase; Y Ohsawa; H Seki; E Takeuchi; H Takano; K Shi; K Takahi; E Kominami; Y Uchiyama; H Yoshikawa; T Ochi
Journal:  Rheumatology (Oxford)       Date:  2001-03       Impact factor: 7.580

10.  Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells.

Authors:  P Saftig; M Hetman; W Schmahl; K Weber; L Heine; H Mossmann; A Köster; B Hess; M Evers; K von Figura
Journal:  EMBO J       Date:  1995-08-01       Impact factor: 11.598

View more
  18 in total

Review 1.  Wound healing and fibrosis in intestinal disease.

Authors:  F Rieder; J Brenmoehl; S Leeb; J Schölmerich; G Rogler
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

2.  Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes.

Authors:  T Spoettl; M Hausmann; M Herlyn; M Gunckel; A Dirmeier; W Falk; H Herfarth; J Schoelmerich; G Rogler
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice.

Authors:  Fiore Cattaruzza; Victoria Lyo; Ella Jones; David Pham; James Hawkins; Kimberley Kirkwood; Eduardo Valdez-Morales; Charles Ibeakanma; Stephen J Vanner; Matthew Bogyo; Nigel W Bunnett
Journal:  Gastroenterology       Date:  2011-07-28       Impact factor: 22.682

4.  TGF-β limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function.

Authors:  Reena Rani; Alan G Smulian; David R Greaves; Simon P Hogan; De'Broski R Herbert
Journal:  Eur J Immunol       Date:  2011-05-27       Impact factor: 5.532

5.  Cathepsin D deficiency is associated with a human neurodegenerative disorder.

Authors:  Robert Steinfeld; Konstanze Reinhardt; Kathrin Schreiber; Merle Hillebrand; Ralph Kraetzner; Wolfgang Bruck; Paul Saftig; Jutta Gartner
Journal:  Am J Hum Genet       Date:  2006-03-29       Impact factor: 11.025

Review 6.  Intestinal antigen-presenting cells in mucosal immune homeostasis: crosstalk between dendritic cells, macrophages and B-cells.

Authors:  Elizabeth R Mann; Xuhang Li
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  Beneficial effects of cathepsin inhibition to prevent chemotherapy-induced intestinal mucositis.

Authors:  I Alamir; N Boukhettala; M Aziz; D Breuillé; P Déchelotte; M Coëffier
Journal:  Clin Exp Immunol       Date:  2010-08-20       Impact factor: 4.330

8.  Upregulation of cathepsin C expression contributes to endothelial chymase activation in preeclampsia.

Authors:  Yang Gu; David F Lewis; J Steven Alexander; Yuping Wang
Journal:  Hypertens Res       Date:  2017-09-07       Impact factor: 3.872

9.  Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo.

Authors:  K Menzel; M Hausmann; F Obermeier; K Schreiter; N Dunger; F Bataille; W Falk; J Scholmerich; H Herfarth; G Rogler
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

10.  Infliximab therapy increases the frequency of circulating CD16(+) monocytes and modifies macrophage cytokine response to bacterial infection.

Authors:  N Nazareth; F Magro; J Silva; M Duro; D Gracio; R Coelho; R Appelberg; G Macedo; A Sarmento
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.